2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy

Muller, Ilaria ORCID: https://orcid.org/0000-0003-2926-0722, Moran, Carla, Lecumberri, Beatriz, Decallonne, Brigitte, Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909, Jones, Joanne and Dayan, Colin M. ORCID: https://orcid.org/0000-0002-6557-3462 2019. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal 8 (4) , pp. 173-185. 10.1159/000500881

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (433kB) | Preview

Abstract

Thyroid dysfunction (TD) frequently occurs as an autoimmune complication of immune reconstitution therapy (IRT), especially in individuals with multiple sclerosis treated with alemtuzumab, a pan-lymphocyte depleting drug with subsequent recovery of immune cell numbers. Less frequently, TD is triggered by highly active antiretroviral therapy (HAART) in patients infected with human immunodeficiency virus (HIV), or patients undergoing bone-marrow/hematopoietic-stem-cell transplantation (BMT/HSCT). In both alemtuzumab-induced TD and HIV/HAART patients, the commonest disorder is Graves’ disease (GD), followed by hypothyroidism and thyroiditis; Graves’ orbitopathy is observed in some GD patients. On the contrary, GD is rare post-BMT/HSCT, where hypothyroidism predominates probably as a consequence of the associated radiation damage. In alemtuzumab-induced TD, the autoantibodies against the thyrotropin receptor (TRAb) play a major role, and 2 main aspects distinguish this condition from the spontaneous form: (1) up to 20% of GD cases exhibit a fluctuating course, with alternating phases of hyper- and hypothyroidism, due to the coexistence of TRAb with stimulating and blocking function; (2) TRAb are also positive in about 70% of hypothyroid patients, with blocking TRAb responsible for nearly half of the cases. The present guidelines will provide up-to-date recommendations and suggestions dedicated to all phases of IRT-induced TD: (1) screening before IRT (recommendations 1–3); (2) monitoring during/after IRT (recommendations 4–7); (3) management of TD post-IRT (recommendations 8–17). The clinical management of IRT-induced TD, and in particular GD, can be challenging. In these guidelines, we propose a summary algorithm which has particular utility for nonspecialist physicians and which is tailored toward management of alemtuzumab-induced TD. However, we recommend prompt referral to specialist endocrinology services following diagnosis of any IRT-induced TD diagnosis, and in particular for pregnant women and those considering pregnancy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Karger
ISSN:	2235-0640
Date of First Compliant Deposit:	20 August 2019
Date of Acceptance:	29 April 2019
Last Modified:	06 May 2023 04:52
URI:	https://orca.cardiff.ac.uk/id/eprint/125031

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item